Market cap
$28 Mln
Recently Viewed
Clear All$6.48
$0.00 (0.00%)As on 29-Feb-2024 09:30EDT
Market cap
$28 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-38 Mln
ROE
-1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
4,357,950
CFO
$-440.82 Mln
EBITDA
$-399.22 Mln
Net Profit
$-462.81 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
| 1.7 | 1.1 | 1.3 | -15.6 | -69.3 | -- | -- |
|
BSE Sensex*
| -8.7 | 5.4 | -7.7 | -4.0 | 8.1 | 9.7 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
| -10.6 | -76.0 | -89.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Freeline Therapeutics Holdings Plc (FRLN)
|
6.5 | 28.2 | 0.6 | -74.1 | -11,456.1 | -179.7 | -- | 0.9 |
| 4.1 | 181.3 | 0.0 | -55.9 | -- | -23.8 | -- | 0.8 |
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type... 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. Read more
CEO & Executive Director
Mr. Michael J. Parini J.D.
CEO & Executive Director
Mr. Michael J. Parini J.D.
Headquarters
Stevenage
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Freeline Therapeutics Holdings Plc (FRLN) is $6.48 (NASDAQ) as of 29-Feb-2024 09:30 EDT. Freeline Therapeutics Holdings Plc (FRLN) has given a return of -69.29% in the last 3 years.
Since, TTM earnings of Freeline Therapeutics Holdings Plc (FRLN) is negative, P/E ratio is not available.
The P/B ratio of Freeline Therapeutics Holdings Plc (FRLN) is 0.95 times as on 29-Feb-2024, a 78 discount to its peers’ median range of 4.29 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of Freeline Therapeutics Holdings Plc (FRLN) are Rs -- and Rs -- as of 04-May-2026.
Freeline Therapeutics Holdings Plc (FRLN) has a market capitalisation of $ 28 Mln as on 29-Feb-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Freeline Therapeutics Holdings Plc (FRLN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.